Jukka Westermarck and his group received the Elias Tillandz -prize
Prof. Jukka Westermarck and his group received the Elias Tillandz -prize for the best publication of the year for his ground-breaking study on that reveals the druggability of type-2A phosphatase, which has been largely regarded as a non-druggable cancer target. Link to study.
Warmest congratulations to the whole team!
Read more:
Recent Posts
- The Academy of Finland granted Johanna Ivaska €2,400,000 in funding for an Academy Professor position The Academy of Finland granted our Group Leader, Professor Johanna Ivaska €2,400,000 in funding for Read moreOctober 30, 2025
- Guillaume Jacquemet and Cecilia Sahlgren receive funding for the Research Council of Finland Centre of Excellence in Immune-Endothelial Interactions (IMMENs) Associate Professor Guillaume Jacquemet, our Group Leader, and Professor Cecilia Sahlgren, our affiliated Group Leader, Read moreOctober 30, 2025
- Registration to AI2Med imaging event is now open! Registration for AI2Med Turku 2025 is open! The event is organized by the Turku PET Read moreOctober 21, 2025
- Jonna Alanko receives the Young Investigator Award from the Scandinavian Society for Immunology Jonna Alanko has received the Young Investigator Award of the Scandinavian Society for Immunology. The Read moreOctober 17, 2025
- Professor Riitta Lahesmaa awarded Johnny Ludvigsson Prize for Outstanding Nordic Researcher Professor Riitta Lahesmaa was awarded Johnny Ludvigsson Prize for Outstanding Nordic Researcher. The prize is Read moreOctober 16, 2025
- PFAS levels in mothers’ blood associated with children’s brain structure and function Researchers from the University of Turku and Turku University Hospital, Finland, and Örebro University, Sweden, Read moreOctober 13, 2025